Stilla and Bio-Rad: A Human Adventure, an Incredible Technology That Will Save Lives

Here is a historic turning point: Stilla Technologies is joining Bio-Rad Laboratories, and with this acquisition, it’s more than just a company scaling up—it’s a revolutionary technology that will spread across the world to save lives!

The Story of a Visionary and an Exceptional Team

At the origin of this adventure is Rémi Dangla, a Jedi among Jedis, a bold scientist who, with his team, turned an idea into a technological revolution. For over ten years, Stilla has pushed the boundaries of digital PCR, developing Nio®, a precision instrument that detects the tiniest, the invisible, serving medical diagnostics and genomic research. Liquid biopsy, cell and gene therapies, infectious diseases, cancer: Stilla provides researchers and clinicians with the tools to better understand, better diagnose, and better treat.

An Industrial Challenge Met in France

But innovation alone is not enough. It must be turned into a product and made accessible to those who need it. That’s where MGA Technologies stepped in, taking on the challenge of designing, in just 18 months, and producing in France a high-precision instrument capable of competing with the best global technologies. Rémi made this industrial bet with the MGA teams, proving that it is possible to innovate and manufacture in France, with excellence and high standards. Even the Red Dot Design Award recognized us in 2024, leading us all the way to the Élysée Palace at the end of October.

With Bio-Rad, a New Horizon Awaits!

Joining Bio-Rad means giving this technology the impact it deserves. With Bio-Rad’s commercial, marketing, and operational power, the instruments developed by Stilla and MGA will be deployed worldwide, in hospitals, research laboratories, and diagnostic centers. It ensures that this technology, born from a vision and relentless hard work, can make a large-scale difference, save lives, and contribute to the rise of more precise and personalized medicine.

Congratulations to Rémi, Stilla, MGA, Bio-Rad, and All Teams!

This success is above all human. It is the story of a visionary entrepreneur, a passionate team, and committed industrial partners. The adventure continues, bigger and stronger, with the same mission: to put technology at the service of life.

Long live La French Fab !
Long live Territoires d’Industrie !
It’s time to SWARM-itc !

Breaking News!
We’re excited to announce that Bio-Rad has offered to acquire Stilla Technologies for up to $275 million, paving the way for the next chapter in this journey!